First Time Loading...

Denali Therapeutics Inc
NASDAQ:DNLI

Watchlist Manager
Denali Therapeutics Inc Logo
Denali Therapeutics Inc
NASDAQ:DNLI
Watchlist
Price: 19.71 USD 2.12%
Updated: May 14, 2024

Denali Therapeutics Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Denali Therapeutics Inc
Research & Development Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Denali Therapeutics Inc
NASDAQ:DNLI
Research & Development
-$423.9m
CAGR 3-Years
-26%
CAGR 5-Years
-24%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Research & Development
-$7B
CAGR 3-Years
-4%
CAGR 5-Years
-6%
CAGR 10-Years
-9%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$6.1B
CAGR 3-Years
18%
CAGR 5-Years
-3%
CAGR 10-Years
-11%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$5B
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.7B
CAGR 3-Years
-26%
CAGR 5-Years
-21%
CAGR 10-Years
-15%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$4.6B
CAGR 3-Years
-17%
CAGR 5-Years
-16%
CAGR 10-Years
-17%

See Also

What is Denali Therapeutics Inc's Research & Development?
Research & Development
-423.9m USD

Based on the financial report for Dec 31, 2023, Denali Therapeutics Inc's Research & Development amounts to -423.9m USD.

What is Denali Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-24%

Over the last year, the Research & Development growth was -18%. The average annual Research & Development growth rates for Denali Therapeutics Inc have been -26% over the past three years , -24% over the past five years .